Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | LGMN | Q99538 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 3/20 | 0.37 |
| ▸ | MMP13 | P45452 | 3/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472651 | 0.83 | HRH3 (0.63) | HRH3 | |
| SCHEMBL2472655 | 0.83 | HRH3 (0.63) | HRH3 | |
| SCHEMBL2635224 | 0.80 | HRH3 (0.58) | HRH3 | |
| SCHEMBL2635228 | 0.80 | HRH3 (0.58) | HRH3 | |
| SCHEMBL2475156 | 0.80 | HRH3 (0.58) | HRH3 | |
| SCHEMBL2477768 | 0.80 | HRH3 (0.58) | HRH3 | |
| SCHEMBL2472661 | 0.80 | HRH3 (0.58) | HRH3 | |
| SCHEMBL2474390 | 0.80 | HRH3 (0.58) | HRH3 | |
| SCHEMBL2479484 | 0.80 | HRH3 (0.58) | HRH3 | |
| SCHEMBL13332128 | 0.78 | HRH3 (0.48) | HRH3F10PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373659-B1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-07-30 | — | — | EP | disclosed |
| EP-2373659-B1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-07-30 | — | — | EP | disclosed |
| US-8383814-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-8383814-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-8383814-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-8217052-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-10 | — | — | US | disclosed |
| US-8217052-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-10 | — | — | US | disclosed |
| US-8217052-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-10 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
| EP-2373659-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065798-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065798-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, HRH1 | HRH3 1/4885EGLN1 545/4885F10 4411/4885 |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, HRH1 | HRH3 1/4885EGLN1 545/4885F10 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.